Skip to content

Inhibrx Biosciences, Inc. INBX Property, plant and equipment at cost

Property, plant and equipment at cost at other companies

Merck & Co. logo
Merck & Co.MRK
Gilead Sciences logo
Gilead SciencesGILD
Nuvation Bio logo
Nuvation BioNUVB
Replimune Group logo
Replimune GroupREPL
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
Incyte logo
IncyteINCY

Other financials

Income statement

See full
Revenue--100%
Operating income-$30.9M+27.9%
Net income-$33.4M+22.8%
EPS (diluted)-$2.15+23.2%

Balance sheet

See full
Cash & equivalents$161.7M-25.3%
Total debt$180.9M+69.8%
Total equity-$21.0M-122%
Total assets$184.0M-24.2%

Cash flow

See full
Operating cash flow-$38.0M-5.9%
CapEx--100%
Free cash flow-$38.0M-5.9%

Valuation

See full
Market cap$1.4B+546%
Enterprise value$1.42B+1,233%
P/S1,073.7×-280×

Profitability

See full
Operating margin-10,386.5%-5,025pp
Net margin-10,773.5%-878,492pp
FCF margin-9,986.5%-4,727pp

Returns & leverage

See full
Return on equity-197.8%-2,158pp
Debt / equity13.4×+13.3×
Current ratio6.5×+1.3×

Where this comes from

Reported directly by Inhibrx Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentGross.

The official record: Inhibrx Biosciences, Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Inhibrx Biosciences, Inc.'s property, plant and equipment at cost.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Inhibrx Biosciences, Inc.'s property, plant and equipment at cost?
Inhibrx Biosciences, Inc. (INBX) reported property, plant and equipment at cost of $14.85M in Q1 2026.
How has Inhibrx Biosciences, Inc.'s property, plant and equipment at cost changed year-over-year?
Inhibrx Biosciences, Inc.'s property, plant and equipment at cost decreased by 1.7% year-over-year, from $15.11M to $14.85M.
What is the long-term trend for Inhibrx Biosciences, Inc.'s property, plant and equipment at cost?
Over 2 years (2023 to 2025), Inhibrx Biosciences, Inc.'s property, plant and equipment at cost has grown at a 6.5% compound annual growth rate (CAGR), from $13.11M to $14.85M.